期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy
1
作者 Zunyi Zhang Wei Zhang 《Hepatobiliary Surgery and Nutrition》 SCIE 2023年第5期772-775,共4页
Cholangiocarcinoma(CCA)encompasses a range of neoplasms,namely intrahepatic CCA,perihilar CCA,and distal CCA,which are distinguished by their anatomical origin.In cases where radical resection of CCA is feasible and t... Cholangiocarcinoma(CCA)encompasses a range of neoplasms,namely intrahepatic CCA,perihilar CCA,and distal CCA,which are distinguished by their anatomical origin.In cases where radical resection of CCA is feasible and the patient’s physical condition permits surgical intervention,it is advisable to proceed with surgical treatment(1).However,the insidious onset of the disease restricts surgical candidacy to only 20-30%of patients(2,3).For those with unresectable CCAs,the recommended initial treatment is gemcitabine plus cisplatin(GemCis)chemotherapy(4). 展开更多
关键词 silmitasertib cholangiocarcinoma(CCA) conversion therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部